Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Inclusion Criteria:

   - Patients must be newly diagnosed with de novo acute myelogenous leukemia

   - Patients with previously untreated primary AML who meet the customary criteria for AML
   with >= 20% bone marrow blasts as set out in the 2008 World Health Organization (WHO)
   Myeloid Neoplasm Classification are eligible

      - Attempts to obtain bone marrow either by aspirate or biopsy must be made unless
      clinically prohibitive; in cases where it is clinically prohibitive, peripheral
      blood with an excess of 20% blasts and in which adequate flow cytometric and
      cytogenetics/fluorescent in situ hybridization (FISH) testing is feasible can be
      substituted for the marrow exam at diagnosis

   - Patients with < 20% bone marrow blasts are eligible if they have:

      - A karyotypic abnormality characteristic of de novo AML (t(8;21)(q22;q22),
      inv(16)(p13q22) or t(16;16)(p13;q22) or 11q23 abnormalities

      - The unequivocal presence of megakaryoblasts, or

      - Biopsy proven isolated myeloid sarcoma (myeloblastoma; chloroma, including
      leukemia cutis)

   - Patients with any performance status are eligible for enrollment

   - Prior therapy with hydroxyurea, all-trans retinoic acid (ATRA), corticosteroids (any
   route), and IT cytarabine given at diagnosis is allowed; hydroxyurea and ATRA must be
   discontinued prior to initiation of protocol therapy; patients who have previously
   received any other chemotherapy, radiation therapy or any other antileukemic therapy
   are not eligible for this protocol

Exclusion Criteria:

   - Patients with any of the following constitutional conditions are not eligible:

      - Fanconi anemia

      - Shwachman syndrome

      - Any other known bone marrow failure syndrome

      - Patients with constitutional trisomy 21 or with constitutional mosaicism of
      trisomy 21 Note: enrollment may occur pending results of clinically indicated
      studies to exclude these conditions

   - Patients with any of the following oncologic diagnoses are not eligible:

      - Any concurrent malignancy

      - Juvenile myelomonocytic leukemia (JMML)

      - Philadelphia chromosome positive AML

      - Biphenotypic or bilineal acute leukemia

      - Acute promyelocytic leukemia

      - Acute myeloid leukemia arising from myelodysplasia

      - Therapy-related myeloid neoplasms Note: enrollment may occur pending results of
      clinically indicated studies to exclude these conditions

   - Pregnancy and breast feeding

   - Female patients who are pregnant are ineligible

   - Lactating females are not eligible unless they have agreed not to breastfeed their
   infants

   - Female patients of childbearing potential are not eligible unless a negative pregnancy
   test result has been obtained

   - Sexually active patients of reproductive potential are not eligible unless they have
   agreed to use an effective contraceptive method for the duration of their study
   participation